all rest our a some the XXXX across of earnings XXXX last Pieris was call. moving to of on begin for Well, thank I very of year. programs. before proprietary would you, and highlights a to today quick progress Tom, and this introduction Pieris thank with to at like year's recap plans you year-end us for marked to everyone and for our joining substantial partnered by our
the of are called a that Anticalins, bind locally various ability transport At they proprietary stable proteins proteins immuno-oncology. doing bispecific versions Anticalins complex in engineered to treat and and smaller, desired delivery formats next-generation unique respiratory such we a treat to are called Pieris, molecules. or lipocalins of inhaled naturally more occurring advantages, to engineerable we than as developed therapeutic have drive are more Because offer which antibodies, disorders class as biology,
which The year Society dose respiratory served assets of and, ERS, core immuno-oncology International last as our or reported lead at these our Respiratory study datasets of interim from PRS-XXX, positive an results ongoing September, from of more multiple-ascending both of Congress, and specific within Anticalin validation franchises Phase of clinical the broadly, platform. Ib Last we presented we European our is oxide, approaches the for are nitric than asthma developing mild with FeNO, well-validated marker airway a XX elevated inhaled IL-X moderate-to-severe patients receptor in PRS-XXX AstraZeneca asthma. parts exhaled inflammation. namely levels, of pharmacokinetics have who with in pharmacodynamics This safety, antagonist that of fractional tolerability, with we collaboration patients billion, clinically alpha and study assessing of per greater the is
milligrams results tolerated with statistically study at observed available of and twice XX X placebo to to ranging PRS-XXX, to reduction administered found ERS significant PRS-XXX safe in levels XX presented was doses over Notably, a at relative milligrams daily all The FeNO all from days. doses. be well
effect doses, dual target systemic an activity dose-dependent for target exclusively from local engagement administered at could dose tested and lowest activity be showed measured or by PRS-XXX on systemic the depending detectable to no Additionally, pSTATX systemic inhibition dose. at ranging the higher local candidate the a as prolonged drug suggesting
for asthma. of very best-in-class inhaled data, encouraged by we a We positions which are the as biologic the PRS-XXX believe potential totality
MAD different the we in have preparations been a doses to pronounced Phase of IIa lower Ib by end additional X-milligram part the cohorts tested observed asthmatics, uncontrolled at moderate-to-severe, study the of sponsored conduct and lower Phase funded dose a in level. given which reduction be the range at previously exploring dose in study, including As ongoing delivered will AstraZeneca, that the was dose levels FeNO
we II in Phase line cohorts, by this AstraZeneca. finalizing enrollments conveyed these are of and a study last expect the will We month year, time the second begin half in
upon Pieris will the study, of have co-commercialize and Phase States. the codevelop As a United options in reminder, IIa completion subsequently to PRS-XXX
Beyond X continue with our advance -- to X AstraZeneca. X-program programs discovery of PRS-XXX, collaboration we X in collaboration
fourth to year. have will discovery the AstraZeneca option initiate this the program
hard plan own. work on half In programs these We proprietary several are of at we data our of the of this one rationale and programs the IND-enabling studies. for to discovery-stage respiratory second also disclose developing advancement year, into
inhaled quarter as approach, we in pathways moderate-to-severe with pursuing driver of IL-X with a elucidation asthma validating novel PhD. signed Anuradha possibilities targets. Anticalin manifestation last the effect, we Dr. and Ray, explore renowned for proteins to committed collaboration Wenzel, and biology with hand are PRS-XXX, complementary of in progression. research inhaled X therapeutic to the involves To University of Dr. of the asthma, Pittsburgh With and in comprehensive professors experts data we positive phenotyping alpha new that pathophysiology and MD our patients clinical receptor of Sally other disease collaboration The
Our industry-leading with ultimate to proprietary targeted respiratory of this build to look more goal of development We is collaboration inhaled novel to strategies portfolio leveraging for streamlined forward therapeutics. an patient couple enrichment therapies. these findings innovative,
our to other core to an like on I'd franchise, now turn update immuno-oncology.
to and which in the entered novel bispecific a of have X-XBB asset, first biology we most is the clinical of a of our X-XBB. clinical And advanced expect second PRS-XXX PRS-XXX, our with bispecific, half effort this partnered part year. ongoing IND first of to is to agonist an lead is broad program, X-XBB/PLD-LX which is file trials. for proprietary Servier, which the tumor-targeted X-XBB deep our is leverage PRS-XXX, at understanding X-XBB/HERX Our Pieris
effects signal proliferation, and cytotoxicity, critical that activated a the unwanted know, As antibody-based to inadequate agonism Fc and in issues receptor, receptors cytokine to X-XBB among conventional factor Targeting expressed killer of gamma a secretion a of lymphocytes, necrosis T cell you mediate to natural tumor the efficacy. X-XBB leads or the member activity. cells cell cells antitumor surface other which hepatotoxicity is through of memory, immune due cell success limited has believed X-XBB T is co-stimulatory on engagement had and on help of T receptor enhanced is liver is approaches cells. provide mediated other T to by super-family
have single successfully so in We PRS-XXX studies both combination objective engineered our therapy a while and effects bispecific achieving avoid clinical as in clinical these far. unwanted X-XBB-based to responses agent
for agonism. Specifically, of the XXX well tolerated for experiencing been signs Cancer, with presented showed the safe biomarker our which and evidence data dose PRS-XXX I no of X-XBB Phase not a had Annual PRS-XXX was for SITC, dose-limiting efficacy at dose-escalation toxicity. as a encouraging promising Immunotherapy last Society Meeting, November, from patient single agent linked studies And to we clear tolerated interim achieved. or of maximum
the which patients in QX of disease. consisted Stage X of of who at one patient the XX X kg responses, partial IV date, achieved stable XXb, five cancer the were three and cancer regimen, objective in weekly As October which patients cutoff Stage evaluated XXX% gastric the control with per patient gynecological with dose and X IV is disease patients Cohort PRS-XXX rate time a milligrams
PRS-XXX in November also data a inhibitor atezolizumab, R&D Day Roche. under of PD-LX in a agreement drug by the from combination I emerging study presented provided We our with event supply Phase dose-escalation at
over tolerated. the regimen combination the were data partial indicated X experiencing was the showing both response well patients an correlative baseline patients X patients. November that deepening several Responding of and responses cutoff XX eightfold whom in increase T of over these There cells cancer and from shrinkage, of partial disease with patients tumor As safe date, biomarker with post-treatment X control. exhibit signature included CDX+ confirmed confirmed in a and breast biopsies
response previously monotherapy. non-small a receiving and confirmed cell patient partial included data after atezolizumab progressing cancer Additional a with lung on
who R&D presentation in have the with soon. progress as the Since all study respect both have look and enrollment well to lot as to November, in we we been enrolling made patients patients, on on studies of completing Day additional a forward of patients
from attributed population share the this the to More a HERX-positive going patients on we're engagement we specifically, in advance clinical our we cancer beyond PRS-XXX homogenous we to Day study to and of for the correlative SITC and data year monotherapy at patients PRS-XXX patient continued X-XBB refined gastric of in design. with additional plan dose. in combination plan development are both and quarter indication, highlights disclosed we a in mobilizing of selected details biomarker the R&D Based on have as our at more PD-LX benefit second in signatures development our which priority show of and emerging at trials, what November, the once
investments the the are As balance guided of high principle between drug of while we appropriate. ensuring candidate our trying exploring potential are we the these finalize by to a shared strike plans, appropriately
our In while plan going additional the details data more time the phase today. of to of giving not specific to finalize are for next datasets the XXX's the of mature interest disclose emerging development, we we
However, intend given data studies at from disclose of therapy a year. these to combination time in the we monotherapy in or Further, line informing present we our of medical this those we the detailed PRS-XXX for the provide studies second to plan, the intend and at escalation these importance data the from conference top results entirety scientific details. half of
the to as into activation have we continuing the microenvironment-localized look efforts well as attractiveness we towards of our one the advancing clinic. bispecifics conviction X-XBB approach, approach XXX of a PRS-XXX in continued both pioneers other of data through development this X-XBB strengthen generated The forward tumor as our for and of and
advanced the our X-XBB with of intend under collaboration most development. And in in is which lead Servier, IND first this rigorous for an second IO and program file IO we PD-LX mentioned, a as half Our year. readiness the the IND to program, program PRS-XXX, bispecific is
And which is finally, on IO and schedule. part franchise an an with rounding Genetics, important remains have IO chapter, collaboration of Seattle our we progressing IO out the
of like call for words Before operations. financial update, few coronavirus, to I say would regarding our to impact a COVID-XX, turning the our the on over or Tom
will the mindful circumstances how evolve. Although impactful it early that to is continue to too be, we're this pandemic tell
in enough clinical to not hotspots products drug We been available we any are running have affected our the and clinical studies. have ongoing date, to any trials of complete that
virus, the have the taking infrastructure if also And precautions allow minimize the limiting We work will to exposure unnecessary employees remotely, that travel. are to many needed. we of necessary in to including place our
situation smoothly, to are continuously best employees doing including that monitoring operations that are continue our to the our we safe course, ensure our and and all Of of laboratories. are run
phases continued we proprietary clinical to XXXX of next and year execution ahead, be our all expect programs, the including across development of PRS-XXX. Looking partnered a into entry successful PRS-XXX for and
the our year-end through like you results. to This remarks, call my guide back over and would XXXX prepared concludes now to I to financial Tom hand
